Cabio Biotech Slumps 20% After Shanghai Risk Warning Over ARA Turmoil

How Cabio’s Infant Formula Ingredient Business Unraveled

Cabio Biotech, the world’s second-largest producer of arachidonic acid (ARA) – a critical omega-6 fatty acid used in infant formula – has been placed under a risk warning by the Shanghai Stock Exchange after overseas regulatory turbulence gutted its operations. When trading resumed on July 28, the stock plunged the maximum 20% allowed, closing at CNY7.95. The shares have now lost nearly 70% of their value this year.

The turmoil traces back to an announcement earlier this year by Swiss food giant Nestlé, which warned that ARA oil supplied by one of its major manufacturers posed potential quality risks. Nestlé launched a precautionary recall of certain infant formula batches across 31 countries and regions. In February, the European Union introduced import controls specifically targeting ARA oil produced in China for use in infant formula, effectively locking Cabio out of a key market.

Cabio disclosed on July 24 that production plans had been adjusted and measures taken to restore operations, but production and sales have yet to fully recover. First-half revenue is expected to collapse 82% year-on-year to CNY55 million (USD8.1 million), swinging from a net profit of CNY108 million a year earlier to a net loss of CNY100.6 million. The company, which relies on human nutrition for 94% of its revenue, is now trying to diversify into animal nutrition and beauty while gradually resuming supplies to a few core human-health customers.

ARA Supply Shock: What Nestlé’s Recall and EU Ban Mean for the Industry

Nestlé’s Recall and the EU’s Import Curbs: A One-Two Punch

The Nestlé recall was the initial shock, shaking confidence in Cabio’s ARA quality. Within weeks, the European Union erected a regulatory barrier that prevents Chinese-produced ARA from entering infant formula sold in the bloc. The two events are probably linked: the EU acted on the same quality concerns that prompted Nestlé’s move. For a company that generated virtually all its sales from human nutrition, the combination destroyed its core revenue stream overnight.

ARA Market Shifts Toward DSM-Firmenich as Cabio Stumbles

Cabio’s crisis hands a dominant position to Swiss-Dutch giant DSM-Firmenich, the world’s top ARA supplier. Infant formula manufacturers that previously bought from Cabio are now likely securing longer-term contracts with DSM-Firmenich to avoid supply-chain disruptions. Given the stringent quality and regulatory requirements in infant nutrition, once customers switch suppliers, they are slow to return – especially when the original supplier is under a risk warning from its own stock exchange.

Cabio’s Diversification: Too Little, Too Late?

Management is touting new orders in animal nutrition and partnerships with beauty brands, but these segments together generated just 3.2% of revenue last year. Scaling them up enough to offset the collapse in human nutrition will take years, not months. The company also says it has resumed shipments to some core human-health customers, likely those outside the EU and unaffected by Nestlé’s recall, but the volume is clearly a fraction of what it once was.

Cabio’s Path to Recovery: Immediate Priorities to Survive the Crisis

• Resolve the quality cloud with Nestlé and EU regulators. Cabio must secure an independent audit of its ARA production and publicly share the findings. A clear, transparent report could open the door for Nestlé to lift its precautionary stance and for the EU to reconsider import controls.
• Present a credible turnaround plan to the STAR board before the three-month deadline. The Shanghai Stock Exchange’s risk warning carries the threat of delisting. The company needs to show measurable progress – restored production volumes, contracted orders, or a path to EU market access – to avoid a permanent removal of the stock.
• Redirect production capacity to non-EU infant formula markets. Markets in Asia, Latin America and the Middle East may still accept Chinese ARA if quality documentation is sufficient. Securing short- and medium-term contracts there can provide a revenue floor while the EU situation remains unresolved.
• Aggressively push animal nutrition and beauty to near-term revenue. The new animal nutrition orders already won should be fulfilled rapidly to generate cash and demonstrate momentum. Cabio should also explore toll manufacturing or white-label deals with major beauty brands that value a quick, reliable supply of DHA and other ingredients.
• Consider strategic alliances or a partial exit from ARA. If EU market access proves impossible to restore, the company may need to partner with a European manufacturer that can produce Cabio’s ARA under license or acquire local production assets, enabling it to bypass the import ban while preserving some of its technical edge.